Aspirin and cancer: biological mechanisms and clinical outcomes.

Peter Elwood, Majd Protty, Gareth Morgan, Janet Pickering, Christine Delon, John Watkins

Open biology 2022 Sep

filter terms:

Evidence on aspirin and cancer comes from two main sources: (1) the effect of aspirin upon biological mechanisms in cancer, and (2) clinical studies of patients with cancer, some of whom take aspirin. A series of systematic literature searches identified published reports relevant to these two sources. The effects of aspirin upon biological mechanisms involved in cancer initiation and growth appear to generate reasonable expectations of effects upon the progress and mortality of cancer. Clinical evidence on aspirin appears overall to be favourable to the use of aspirin, but evidence from randomized trials is limited, and inconsistent. The main body of evidence comes from meta-analyses of observational studies of patients with a wide range of cancers, about 25% of whom were taking aspirin. Heterogeneity is large but, overall, aspirin is associated with increases in survival and reductions in metastatic spread and vascular complications of different cancers. It is important that evaluations of aspirin used as an adjunct cancer treatment are based upon all the available relevant evidence, and there appears to be a marked harmony between the effects of aspirin upon biological mechanisms and upon the clinical progress of cancer.

Citation

Peter Elwood, Majd Protty, Gareth Morgan, Janet Pickering, Christine Delon, John Watkins. Aspirin and cancer: biological mechanisms and clinical outcomes. Open biology. 2022 Sep;12(9):220124